Werewolf Therapeutics Inc (NASDAQ: HOWL) is -25.00% lower on its value in year-to-date trading and has touched a low of $0.60 and a high of $5.73 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The HOWL stock was last observed hovering at around $0.99 in the last trading session, with the day’s gains setting it 0.12%.
Currently trading at $1.11, the stock is 21.86% and 15.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.3 million and changing 12.12% at the moment leaves the stock -32.81% off its SMA200. HOWL registered -75.11% loss for a year compared to 6-month loss of -49.55%.
The stock witnessed a 29.40% gain in the last 1 month and extending the period to 3 months gives it a -26.49%, and is 27.59% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.29% over the week and 10.94% over the month.
Werewolf Therapeutics Inc (HOWL) has around 46 employees, a market worth around $49.80M and $1.14M in sales. Profit margin for the company is -6335.17%. Distance from 52-week low is 86.55% and -80.63% from its 52-week high. The company has generated returns on investments over the last 12 months (-77.94%).
The EPS is expected to shrink by -9.00% this year
The shares outstanding are 44.83M, and float is at 33.04M with Short Float at 6.50%.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 6.14 million shares valued at $14.99 million. The investor’s holdings represent 14.7688 of the HOWL Shares outstanding. As of 2024-06-30, the second largest holder is MPM ASSET MANAGEMENT LLC with 4.28 million shares valued at $10.45 million to account for 10.2967 of the shares outstanding. The other top investors are PFM HEALTH SCIENCES, LP which holds 3.24 million shares representing 7.7897 and valued at over $7.91 million, while BIOIMPACT CAPITAL LLC holds 5.7394 of the shares totaling 2.39 million with a market value of $5.83 million.
Werewolf Therapeutics Inc (HOWL) Insider Activity
The most recent transaction is an insider purchase by RA CAPITAL MANAGEMENT, L.P., the company’s Director. SEC filings show that RA CAPITAL MANAGEMENT, L.P. bought 320,913 shares of the company’s common stock on May 12 ’25 at a price of $0.86 per share for a total of $0.28 million. Following the purchase, the insider now owns 6.02 million shares.
Werewolf Therapeutics Inc disclosed in a document filed with the SEC on May 14 ’25 that RA CAPITAL MANAGEMENT, L.P. (Director) bought a total of 162,539 shares of the company’s common stock. The trade occurred on May 14 ’25 and was made at $0.98 per share for $0.16 million. Following the transaction, the insider now directly holds 6.24 million shares of the HOWL stock.
Still, SEC filings show that on May 13 ’25, RA CAPITAL MANAGEMENT, L.P. (Director) acquired 52,974 shares at an average price of $0.98 for $51915.0. The insider now directly holds 6,074,943 shares of Werewolf Therapeutics Inc (HOWL).
